⏰NOW OUT‼️ #ASCO24 Abstract Titles
🔥Lung Cancer - Non-Small Cell Metastatic
☑️ #LBA8500 EVOKE-01 Luis Paz-Ares
☑️#8501 ICARUS-LUNG01 d.planchard
☑️ #LBA8503 CROWN Ben Solomon
☑️#8504 MARIPOSA Enriqueta Felip
☑️ #LBA8505 PALOMA-3 Dr.Natasha Leighl
and others
#LCSM OncoAlert ASCO

A timely discussion with Narjust Florez, MD, FASCO amazing host of @iaslc Lung Cancer Considered podcast about the ALINA trial given the recent U.S. FDA approval of adjuvant alectinib for resected ALK+ NSCLC! Thanks Narjust Florez, MD, FASCO ! #LCSM

FDA approved alectinib for adjuvant treatment following tumor resection in patients with ALK-positive non-small cell lung cancer, as detected by an FDA-approved test.
fda.gov/drugs/resource…
#OCENewsBurst #lcsm #nsclc

Breaking: FDA approval of adjuvant alectinib for patients with resected #ALK fusion positive NSCLC. Approval based on phase III ALINA trial where adjuvant alectinib profoundly improved disease free survival (DFS HR 0.24) with CNS DFS HR 0.22! #LCSM

gene.com/media/press-re…

#Alectinib now FDA Oncology approved based off #ALINA trial.

Alectinib vs Chemo post resection in NSCLC, Stg Ib-IIIA:

- Alectinib for 2 yrs
- Improved DFS in all subgroups: HR0.24
- Improved CNS DFS HR: 0.22
- New Soc

Ben Solomon #lcsm #onctwitter #medtwitter

In the ALINA trial of adjuvant treatment for patients with resected ALK-positive non–small-cell lung cancer, disease-free survival at 2 years was 93.6% with the ALK inhibitor alectinib & 63.7% with standard chemotherapy. Full results & Research Summary: nej.md/3VUzf3M

🛎 just published in NEJM our editorial on the groundbreaking ALINA trial, evaluating the role of adjuvant alectinib in patients with resected NSCLC carrying ALK rearrangements.
A major advance for our patients!
🔗nejm.org/doi/full/10.10…

In the ALINA phase 3 trial of adjuvant treatment for patients with resected ALK-positive non–small-cell lung cancer, disease-free survival at 2 years was 93.6% with the ALK inhibitor alectinib and 63.7% with standard chemotherapy. Full trial results: nej.md/3VUzf3M

Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer | New England Journal of Medicine nejm.org/doi/full/10.10…

#WCLC24 abstracts are due Friday! Who’s already submitted ? 😂
#lcsm IASLC

Just released - thank you for a great cooperation!
Evolution of Oncogenic-Driven Early-Stage Resectable NSCLC: Testing and Practical Considerations medscape.org/viewarticle/10… via Medscape Education Eric Lim Ben Solomon @Medscape

What a great #ELCC24 in the beautiful city of #Prague - great science, great collaborations and catching up with friends and colleagues from across the 🌏

Really good to meet up with colleague Ben Solomon from Peter Mac Cancer Centre - good to see you Ben!

Congratulations to the dynamic duo Daniel Steinfort and Shankar Siva on publication of the SEISMIC study showing the importance of systematic mediastinal node sampling in patients with early stage and locally advanced NSCLC The Lancet Respiratory Medicine 👏🏽👏🏽

Real world outcomes in pts with #ALK NSCLC (US, 2011-20, 739 pts) JTO & JTO CRR. mOS was 37 months. Better outcomes with no smoking history, younger age, academic hospitals, earlier stage at diagnosis.

jtocrr.org/article/S2666-…

The #IASLC needs your input! 🙏Take this Biomarker Testing Survey & help to improve care worldwide. The survey is available in 6 languages & takes just a few minutes. bit.ly/BiomarkerS24 #LCSM . A BIG THANK YOU!!

Two rockstars on Stage in Sydney today! #LCSM

Ready for #ITCD2024 to start in Gran Canaria! Alfredo Addeo MD Ben Solomon Julia Rotow MD Claudia Proto Dr. Antonio Calles 🫁🚭 #LCSM

Next step in the US following the ALINA #clinicaltrial for early stage ALK+ #lungcancer :

FDA Grants Priority Review to Alectinib for ALK+ NSCLC cancernetwork.com/view/fda-grant… via CancerNetwork® #LCSM

Was a real pleasure to chat with the phenomenal Narjust Florez, MD, FASCO about the ALINA trial of adjuvant Alectinib for @iaslc Lung Cancer Considered podcast - coming soon! #LCSM